TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21455255
Drug: DOC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOC group (docetaxel at 75 mg/m² on day 1)
Study: 24944393
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 1)
Study: 24944393
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 2)
Study: 8855179
Drug: Ciprofloxacin and
Normalized name: ciprofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin and a combination of amoxicillin and clavulanic acid for 3 days after hemorrhage (group 3)
Study: 1900488
Drug: Estrogen/progestin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/progestin administration
Study: 31987245
Drug: Isometric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isometric treatment
Study: 19307437
Drug: Compression, sclerotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression, sclerotherapy, surgery, and endoluminal treatments
Study: 15493034
Drug: Antimycotic self-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimycotic self-treatment with antifungal oral gel and antiseptic solution for dentures
Study: 8141577
Drug: Foscarnet induction
Normalized name: foscarnet Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet induction treatment
Study: 3125973
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thymostimulin (TS) i.m. daily for 35 days (G1)
Study: 3125973
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thymostimulin (TS) i.m. every other day for 35 days (G2)
Study: 3125973
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (G3)
Study: 3125973
Drug: Thymostimulin maintenance
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin maintenance therapy
Study: 3125973
Drug: Thymostimulin treatment
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin treatment
Study: 30597771
Drug: PF-04447943 25
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PF-04447943 25 mg
Study: 26548737
Drug: Typical chiropractic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical chiropractic care only (manual therapy and exercises)
Study: 26548737
Drug: Typical chiropractic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical chiropractic care with daily home use of the self-acupressure pillow (SAP)
Study: 18452778
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy (switched from UFH/ENOX)
Study: 18452778
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy (naive to antithrombin therapy)
Study: 18452778
Drug: UFH/ENOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH/ENOX plus GP IIb/IIIa inhibitor (consistent therapy)
Study: 18452778
Drug: UFH/ENOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH/ENOX plus GP IIb/IIIa inhibitor (naive patients)
Study: 11074742
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler plus nicotine patch (delivering 15 mg of nicotine per 16 hours) for 6 weeks, then inhaler plus placebo patch for 6 weeks, then inhaler alone for 14 weeks
Study: 11074742
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler plus placebo patch for 12 weeks, then inhaler for 14 weeks
Study: 2866966
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Atenolol (Control Beta-blockers)
Study: 30657353
Drug: Prediction-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction-based treatment
Study: 28482405
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon α‐2b (Y shape, 40 kD) injection (180 µg/week) combined with ribavirin
Study: 28482405
Drug: Standard-dose Peg‐IFN‐α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose Peg‐IFN‐α‐2a combined with ribavirin
Study: 25064421
Drug: STAGE‐12 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAGE‐12 therapy (high exposure, n=158)
Study: 16982815
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 8 mL/sec
Study: 16982815
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 4 mL/sec
Study: 16982815
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 8 mL/sec with individualized scan delay
Study: 16982815
Drug: Flow rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flow rate of 4 mL/sec with fixed scan delay
Study: 11103232
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CDDP and 5-FU with chemo- and radiotherapy
Study: 8882105
Drug: Topical 4%
Normalized name: menthol topical 4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 4% lidocaine with antibiotic drops
Study: 8882105
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with antibiotic drops
Study: 28893875
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg zoledronate
Study: 28893875
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg zoledronate
Study: 19050050
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg zoledronate
Study: 22072741
Drug: zoledronate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: zoledronate (all doses)
Study: 29151034
Drug: ezetimibe/simvastatin 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/40 mg
Study: 20487050
Drug: rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5 or 10 mg
Study: 18579811
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral rivaroxaban once daily
Study: 18579811
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of enoxaparin subcutaneously once daily
Study: 16049380
Drug: EASI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EASI plus high dose oxytocin
Study: 12444817
Drug: Fluoxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 20 to 80 mg/day (N = 30)
Study: 10638387
Drug: Paracetamol 10
Normalized name: Paracetamol 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 10 mg/kg thrice daily
Study: 10638387
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg thrice daily
Study: 10638387
Drug: Nimesulide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 2.5 mg/kg twice daily for 5 days
Study: 7569731
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) supplementation, 4 g per day for 6 months
Study: 1940932
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg three times daily for 10 days starting on the first postoperative day
Study: 6266028
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin, 5000 units (Ul) 2 hours and 30 minutes before surgery then every 12 hours for 15 days (Protocol A)
Study: 6266028
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin, same dose and duration starting 24 to 72 hours after surgery (Protocol B)
Study: 6266028
Drug: No anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anticoagulant treatment (Protocol O)
Study: 30863894
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose soy drink (35 mg/day isoflavones) for 12 weeks
Study: 30863894
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose soy drink (10 mg/day isoflavones) for 12 weeks
Study: 30863894
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose soy drink (60 mg/day isoflavones) for 12 weeks
Study: 31250285
Drug: SHAM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHAM treatment
Study: 21251813
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (n=79)
Study: 21251813
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (n=77)
Study: 19703948
Drug: Vulnamin gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vulnamin gel with elastocompression
Study: 19703948
Drug: Inert gel
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert gel vehicle with elastocompression
Study: 8622022
Drug: CEF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF chemotherapy (first-line treatment)
Study: 18562328
Drug: Anthracycline-based adjuvant
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based adjuvant chemotherapy
Study: 8622022
Drug: Not receiving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receiving adjuvant chemotherapy
Study: 7326852
Drug: 40 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 micrograms of triiodothyronine (T3) daily
Study: 24046400
Drug: Diluent containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent containing 0.30 µg of 25(OH)D3
Study: 24046400
Drug: Diluent containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent containing 0.60 µg of 25(OH)D3
Study: 24046400
Drug: Diluent containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent containing 1.20 µg of 25(OH)D3
Study: 21492164
Drug: Oltipraz 60
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 60 mg bid for 24 weeks
Study: 21492164
Drug: Oltipraz 90
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 90 mg qd for 24 weeks
Study: 16472330
Drug: rizatriptan 10-mg
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rizatriptan 10-mg wafer
Study: 15658651
Drug: Liuwei Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liuwei Dihuang Pill (LDP) plus conventional therapy (Gliquidone or insulin) for 3 months
Study: 15658651
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Gliquidone or insulin)
Study: 10027034
Drug: 10% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% lidocaine aerosol (2.5-4.7 mg kg-1)
Study: 7628183
Drug: Zifrosilone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zifrosilone 10 mg
Study: 7628183
Drug: Zifrosilone 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zifrosilone 300 mg
Study: 7628183
Drug: Zifrosilone doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zifrosilone doses > or = 200 mg
Study: 7018557
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oestriol gel
Study: 7018557
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg PGF2 alpha gel
Study: 2673340
Drug: gel alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel alone (control)
Study: 30010353
Drug: Tension Tamer
Normalized name: Ascorbic Acid/Chamomile/Cyanocobalamin/Kava/Magnesium/Pyridoxine/St John's Wort 150 MG-100 MG-0.006 MG-100 MG-25 MG-3 MG-50 MG Oral Capsule [TENSION TAMER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tension Tamer (TT) guided BAM sessions for 5-, 10-, or 15-min intervals twice daily over 6 months
Study: 27657471
Drug: Nicorandil (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (5mg thrice daily for 12 weeks)
Study: 27657471
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus nicorandil
Study: 24767094
Drug: Higher volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher volume of whole blood (30 ml/kg; Tx30)
Study: 24767094
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume of whole blood (20 ml/kg; Tx20)
Study: 22218843
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg oral, 12-week treatment)
Study: 22218843
Drug: Placebo (look-alike,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (look-alike, 12-week treatment)
Study: 7594336
Drug: lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole (30 mg/day)
Study: 28541646
Drug: Cognitive Rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Study: 30104294
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 units/mL (Gla‐300)
Study: 28418213
Drug: Lidocaine (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (0.25, 0.50, 1.0 or 10 mg/mL)
Study: 21595743
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg/day for 7 days
Study: 21595743
Drug: Anti-TNF (adalimumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF (adalimumab, Humira®) 40 mg s.c. single dose
Study: 11679026
Drug: Passiflora extract
Normalized name: Passiflora incarnata extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora extract 45 drops/day plus placebo tablet
Study: 11679026
Drug: Oxazepam 30
Normalized name: oxazepam 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 30 mg/day plus placebo drops
Study: 7889022
Drug: Injectable haloperidol
Normalized name: haloperidol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable haloperidol decanoate 141 mg/ml (test product)
Study: 30544411
Drug: Oxycodone 4
Normalized name: OXYCODONE 4.88MG/ASA 325MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 4 mg (group O)
Study: 30544411
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg (group F)
Study: 27166238
Drug: JZP-110 150
Normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP-110 150 mg/day weeks 1-4 and 300 mg/day weeks 5-12
Study: 19057854
Drug: rhu EPO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhu EPO, 500u per kg, per week, 2 times weekly, subcutaneous
Study: 16176313
Drug: Sevoflurane anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane anesthesia with mivacurium (0.2 mg.kg(‐1))
Study: 16176313
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia with mivacurium (0.2 mg.kg(‐1))
Study: 9063758
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg
Study: 9063758
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg
Study: 9063758
Drug: Policosanol 20
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 20 mg
Study: 9063758
Drug: Policosanol 25
Normalized name: Cayenne/Garlic/Guggulsterone/Niacin/Phytosterols/Policosanol 25 MG-25 MG-50 MG-25 MG-100 MG-5 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 25 mg
Study: 9063758
Drug: Policosanol 50
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 50 mg
Study: 10959738
Drug: Oral Polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Polio Vaccine (OPV)
Study: 1845806
Drug: Enhanced-Potency Inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced-Potency Inactivated Polio Vaccine (E-IPV)
Study: 6338689
Drug: Digoxin 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.375 mg
Study: 22947589
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU weekly for 8 weeks
Study: 15124669
Drug: High-dose AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AraC during induction therapy
Study: 15124669
Drug: Standard-dose AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose AraC during induction therapy
Study: 15124669
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF priming
Study: 7913644
Drug: Metipranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metipranolol (3 mg/ml)
Study: 7913644
Drug: Clonidine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2.5 mg/ml)
Study: 7913644
Drug: Clonidine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2.5 mg/ml) and Metipranolol (3 mg/ml)
Study: 23200592
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume reduction coil treatment (LVRC)
Study: 17425783
Drug: Abatacept (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (750 mg infusion)
Study: 17425783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (vaccines on day 1 only)
Study: 9500570
Drug: acute hyperglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: acute hyperglycemic hyperinsulinemia (HG) with plasma glucose at 15 mmol/L
Study: 9500570
Drug: euglycemic hyperinsulinemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: euglycemic hyperinsulinemia (HI) with plasma insulin at 80 mU/L and glucose at 4 to 5 mmol/L
Study: 9500570
Drug: intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (i.v.) saline (control)
Study: 343509
Drug: Theophylline ethylenediamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline ethylenediamine, 400 mg orally
Study: 343509
Drug: Bendroflumethiazide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide, 5 mg orally
Study: 24582466
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other treatment groups
Study: 22430457
Drug: Shifts in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts in BMI category (e.g., overweight to healthy weight)
Study: 22430457
Drug: Shifts in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shifts in BMI category (e.g., healthy weight to overweight)
Study: 11712773
Drug: INVEST (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: INVEST (treatment for 12 months)
Study: 9613267
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.125 mg
Study: 9613267
Drug: Intrathecal diamorphine
Normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal diamorphine 0.375 mg
Study: 7815243
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (10-12 mg/kg/day)
Study: 7815243
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid with taurine (18-22 mg/kg/day)
Study: 1662233
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg IVIG (Gammagard)
Study: 1662233
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg IVIG (Gammagard)
Study: 373921
Drug: Domperidone 2
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 2 mg/ml injected IV 1 hour before cytostatic treatment and again 4 hours later
Study: 373921
Drug: Placebo injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected IV 1 hour before cytostatic treatment and again 4 hours later
Study: 373921
Drug: Domperidone 2
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 2 mg/ml
Study: 26032934
Drug: Chemical peeling
Normalized name: orange peel extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical peeling combined with physical effect (4% AHA solution)
Study: 22277458
Drug: High-dose dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dabigatran
Study: 22277458
Drug: Low-dose dabigatran
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dabigatran
Study: 25739533
Drug: Dabigatran (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (both doses)
Study: 10569322
Drug: treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment effects on ambulatory ischemia
Study: 6349651
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (300 mg per day for 6 weeks)
Study: 6349651
Drug: Phenylbutazone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone (500 mg per day for 1 week and 300 mg per day for 5 weeks)
Study: 6349651
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg per day for 6 weeks)
Study: 28602417
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation therapy (25 Gy in 5 fractions, arm 1)